Kansenshogaku Zasshi
Online ISSN : 1884-569X
Print ISSN : 0387-5911
ISSN-L : 0387-5911
Clinical Study of Balofloxacin on Infectious Enteritis and Assessment of the Fecal Drug Concentration and Intestinal Microbial Flora in Patients with Infectious Enteritis
Mitsuo OBANAShoichiro IRIMAJIRIIsao TOMIZAWAYoshihiko TAKIZAWAYumiko SAKAMOTOYoshiro NITTATakafumi TSUNODAHiroyuki FUKUDATsuyoshi YAMAGUCHIGohta MASUDAMasayoshi NEGISHIAtsushi AJISAWAMisako MURATAKenji OHNISHIHiroko SAGARAYoshikiyo SAJIMAFumio MATSUMOTOTakero IMAIIwao SAKURAITakayuki TAKAHASHIKoji KATOMasamiki MORIShiro HOSODATadao BAMBAMasaya SASAKIKenichi TATEWAKIKenji FUSEHiroshi SAKUMOTOYoshiaki IWASAKIHideo OHKUBOYong-ki KIMMitsuru AKAOYoshihiro SAKAUEKaneko TOJOJunko AMATSUHideki YOSHIDAKunio YOSHIKAWATadakazu AISAKAMotoko MIKAMIOsamu KURIMURAKazunori KAGAWAYoshio MATSUBARAYatsuka IMAGAWAMasafumi FUKUYAMAMakoto SAITO
Author information
JOURNAL FREE ACCESS

1995 Volume 69 Issue 9 Pages 991-1006

Details
Abstract

The efficacy, safety and usefulness of balofloxacin (BLFX) for patients with acute infectious enteritis and the carriers mainly shigellosis, were investigated. The drug was administered at a daily dose of 200 mg twice a day for 3 days to patients with cholera, 7 days to patients with Salmonella enteritis and 5 days to patients with other conditions of infectious enteritis including shigellosis;
1. The efficacy was analyzed in 89 of the 135 patients who received the administration (43 patients with shigellosis, 14 with Salmonella enteritis, 8 with enteropathogenic/enterotoxigenic Escherichia coli enteritis, 3 with cholera, 7 with enteritis with other pathogenic bacteria, 6 with polymicrobial infectious enteritis and 8 with acute enteritis that was pathogen-negative).
2. In patients bearing symptoms and who thus could be analyzed for drug efficacy, the drug was markedly effective or effective 50/52 (96.2%).
3. Bacteriologically, the drug was effective for Shigella spp. in 41 (100%) of 41, Salmonella spp. in 12 (85.7%) of 14, and enteropathogenic/enterotoxigenic Escherichia coli in 8 of 8 cases.
4. Adverse effects were seen in 5/133 patients (3.8%) receiving the drug, including two cases of skin eruption, one of numbness of the hands, one of oral aphtha, and one of nausea. In patients for whom laboratory findings were available, 20/115 (17.4%) showed abnormalities, mainly elevations of GOT and/or GPT, but these were slight.
5. In terms of subjective reports of usefulness, 51/82 (62.2%) were markedly satisfied, and 73/82 (89.0%) were either satisfied or markedly satisfied.
6. The influence of administration of BLFX on fecal concentration and intestinal microbial flora was investigated in 2 patients with acute infectious enteritis. Results approximately equivalent to such flora levels in healthy subjects were obtained.
These results suggest that BLFX is highly useful for infectious enteritis such as that caused by shigellosis.

Content from these authors
© The Japansese Association for Infectious Diseases
Previous article Next article
feedback
Top